Navigation Links
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
Date:12/1/2008

-- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML --

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced new data from its studies of voreloxin in acute myeloid leukemia (AML) will be presented during the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 5-9, 2008. Researchers will present updated interim data from the company's ongoing Phase 2 clinical trial of single-agent voreloxin (formerly SNS-595) for elderly patients with newly diagnosed AML and from its Phase 1b/2 study of voreloxin in combination with cytarabine for relapsed/refractory AML. In addition, results from the Phase 1 study of SNS-032, a selective inhibitor of cyclin dependent kinases 2, 7 and 9, in both chronic lymphocytic leukemia and multiple myeloma will be presented. Following are the details on each of these data presentations.

Sunday, December 7, 2008

Viewing: 9:00 a.m. to 8:00 p.m. PT

Presentation Time: 6:00 p.m. to 8:00 p.m. PT

Hall A, MosconeCenter

Abstract #1951

Title: "Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study)"

Poster Board II-45

Abstract #1955

Title: "Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia"

Pos
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
2. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
3. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
4. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
6. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
9. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary ... SAM Junctional Tourniquet.  Photo - ... Products announced today that it has begun notifying ... potential issue with a clip used to secure ... of the SAM Junctional Tourniquet (SJT).  The company ...
(Date:8/29/2014)... PARK, Calif. , Aug. 29, 2014 ... Medical as CEO and member of the Board of ... decades of medical device development and commercialization experience, including ... field. Mr. Engelson previously served as a Partner of ... as President and CEO of two Foundry start-ups. Mr. ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... 2011 CRC Health Group, the nation,s largest ... today announced the successful acquisition of North Carolina,s ... Solutions, comprised of two facilities located in Asheville ... program by the U.S. Department of Health and ...
... Inc., a leader in medical billing and practice management for ... clients are highly satisfied with its services, according to the ... percent of those surveyed said they would recommend Orion to ... physician groups, laboratories, imaging centers and other healthcare provider clients ...
Cached Medicine Technology:CRC Health Group Announces Acquisition of North Carolina's Mountain Health Solutions 2Orion HealthCorp Gets High Marks From Clients 2
(Date:9/1/2014)... 01, 2014 Parties involved in federally-filed ... the litigation’s status conference in September, where issues related ... in the Eastern District of Pennsylvania, Bernstein Liebhard LLP ... conferences posted on the Court’s website, the meeting is ... 10:00 a.m. This is the latest of several Tylenol ...
(Date:9/1/2014)... 01, 2014 Ontraport , one ... that was developed to automate the small intricacies of ... of Shane Michaels, prompting an investigative review. , ... duty of managing all of the small details involved ... overwhelming,” reports Michaels. “That’s why Ontraport has become so ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... US FDA announced on August 28, that specific lots ... (Class I) as the device may reverse directions ... Synthes Craniomaxillofacial (CMF) Distraction System is an implant used ...
(Date:9/1/2014)... Nevada (PRWEB) September 01, 2014 Beginning ... to over 3,000 medical professionals and 10,000 consumers for ... is a 5-day gathering of the nation’s top medical ... associated diseases or conditions. The week-long event contains more ... evidence-based scientific instruction available in the pain management field. ...
(Date:8/31/2014)... 2014 An analysis of 32 studies ... revealed a link between lower levels of Vitamin D ... the August 2014 issue of American Journal ... form of Vitamin D found in blood. , ... D lower than 9 nanograms/milliliter (ng/mL) were twice as ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4
... the Queen Silvia Children,s Hospital has developed a method that ... a CT scan while still obtaining good image quality, reveals ... an advanced form of X-ray examination which generates images that ... the dose of radiation is lowered too far, however, the ...
... , MONDAY, April 4 (HealthDay News) -- People with ... new study suggests. It also found that a decrease ... abuse and mood disorders. Researchers analyzed data from nearly ... the U.S. National Epidemiologic Survey of Alcohol and Related Conditions. ...
... Eran Shor, working in collaboration with researchers from Stony ... of premature mortality by 63 per cent. Shor reached ... people in 15 (mainly western) countries, over the last ... in spite of expectations that a better health-care system ...
... HealthDay Reporter , MONDAY, April 4 (HealthDay News) -- Heavy ... metabolism of alcohol may face a higher risk than others ... a certain genetic variant and drinking roughly three ... markedly increase the risk of "non-cardia gastric cancer," a study ...
... 2011) The gender gap among United States Medical ... surgery is shrinking, according to study results published in ... American College of Surgeons . These findings align with ... medical students. The study found a 22 percent ...
... Goodwin HealthDay Reporter , MONDAY, April ... use of most medications for treating autism in ... risperidone and aripiprazole that have shown success in ... new study shows. However, anti-psychotics can have ...
Cached Medicine News:Health News:Safer CT scanning for children developed at the Queen Silvia Children's Hospital 2Health News:Poverty Linked to Anxiety, Mood Disorders 2Health News:Men who lose their jobs at greater risk of dying prematurely 2Health News:Heavy Beer Drinking, Genetics May Raise Risk of Stomach Cancer 2Health News:Heavy Beer Drinking, Genetics May Raise Risk of Stomach Cancer 3Health News:More women medical students select general surgery and continue to close the gender gap 2Health News:Evidence Weak to Support Many Medications for Autism: Study 2Health News:Evidence Weak to Support Many Medications for Autism: Study 3Health News:Evidence Weak to Support Many Medications for Autism: Study 4
... West Nile Virus IgG DxSelect is ... West Nile virus in human,serum. In ... Nile Virus,IgM Capture DxSelect, the test ... of meningioencephalitis, as an aid in ...
... PachPen uses state-of-the-art waveform analysis ... at a 65MHz rate to ... stores and averages nine measurements ... pen fits comfortably into the ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
Conducting disposable filter-tips....
Medicine Products: